Tags

Type your tag names separated by a space and hit enter

Loracarbef (LY 163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis.
Ear Nose Throat J. 1992 May; 71(5):225-32.EN

Abstract

Loracarbef (LY 163892), a beta-lactam antibiotic (carbacephem), was compared with amoxicillin/clavulanate potassium in a 10-day, single-blind, randomized parallel trial in the treatment of acute bacterial maxillary sinusitis. Based on posttherapy aspirate and culture, there was a 95.2% bacteriologic cure rate in patients receiving loracarbef (400 mg twice daily) and an 86.7% cure rate in patients receiving amoxicillin/clavulanate (500/125 mg three times daily) (p = 0.359). Loracarbef was comparable in efficacy to amoxicillin/clavulanate with a more desirable safety profile.

Authors+Show Affiliations

Lilly Research Laboratories, Indianapolis, IN.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

1505371

Citation

Sydnor, T A., et al. "Loracarbef (LY 163892) Vs Amoxicillin/clavulanate in Bacterial Maxillary Sinusitis." Ear, Nose, & Throat Journal, vol. 71, no. 5, 1992, pp. 225-32.
Sydnor TA, Scheld WM, Gwaltney J, et al. Loracarbef (LY 163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis. Ear Nose Throat J. 1992;71(5):225-32.
Sydnor, T. A., Scheld, W. M., Gwaltney, J., Nielsen, R. W., Huck, W., & Therasse, D. G. (1992). Loracarbef (LY 163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis. Ear, Nose, & Throat Journal, 71(5), 225-32.
Sydnor TA, et al. Loracarbef (LY 163892) Vs Amoxicillin/clavulanate in Bacterial Maxillary Sinusitis. Ear Nose Throat J. 1992;71(5):225-32. PubMed PMID: 1505371.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Loracarbef (LY 163892) vs amoxicillin/clavulanate in bacterial maxillary sinusitis. AU - Sydnor,T A,Jr AU - Scheld,W M, AU - Gwaltney,J,Jr AU - Nielsen,R W, AU - Huck,W, AU - Therasse,D G, PY - 1992/5/11/pubmed PY - 2001/3/28/medline PY - 1992/5/11/entrez SP - 225 EP - 32 JF - Ear, nose, & throat journal JO - Ear Nose Throat J VL - 71 IS - 5 N2 - Loracarbef (LY 163892), a beta-lactam antibiotic (carbacephem), was compared with amoxicillin/clavulanate potassium in a 10-day, single-blind, randomized parallel trial in the treatment of acute bacterial maxillary sinusitis. Based on posttherapy aspirate and culture, there was a 95.2% bacteriologic cure rate in patients receiving loracarbef (400 mg twice daily) and an 86.7% cure rate in patients receiving amoxicillin/clavulanate (500/125 mg three times daily) (p = 0.359). Loracarbef was comparable in efficacy to amoxicillin/clavulanate with a more desirable safety profile. SN - 0145-5613 UR - https://www.unboundmedicine.com/medline/citation/1505371/Loracarbef__LY_163892__vs_amoxicillin/clavulanate_in_bacterial_maxillary_sinusitis_ DB - PRIME DP - Unbound Medicine ER -